Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus

키워드

참고문헌 (45)

1. "Diabetes Fact Sheet in Korea 2016" (2011)[URL]
2. Nathan DM, "The diabetes control and complications trial", epidemiology of diabetes interventions and complications study at 30 years: overview, 2014, pp.37, 9~16
3. Kyoung Hwa Ha, "Current status of managing diabetes mellitus in Korea", The Korean Journal of Internal Medicine, 31(5), pp.845~850 (2016), 대한내과학회[DOI]
4. American Diabetes Association., "8. Pharmacologic approaches to glycemic treatment", Diabetes Care, 40(Suppl 1), pp.S64~S74 (2017)
5. Garber AJ, "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm:2017 executive summary", Endocr Pract, 23, pp.207~238 (2017)
6. Maruthur NM, "Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis", Ann Intern Med, 164, pp.740~751 (2016)
7. Mishriky BM, "The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2diabetes: a systematic review and meta-analysis", Diabetes Res Clin Pract, 109, pp.378~388 (2015)
8. Palmer SC, "Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis", JAMA, 316, pp.313~324 (2016)
9. Zhou JB, "The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial", Int J Clin Pract, 70, pp.132~141 (2016)
10. Foroutan N, "Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis", Clin Invest Med, 39, pp.E48~E62 (2016)
11. Amate JM, "Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis", Int J Clin Pract, 69, pp.292~304 (2015)
12. Seong JM, "Differential cardiovas cular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study", PLoS One, 10, pp.E0124287~ (2015)
13. Storgaard H, "Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis", PLoS One, 11, pp.e0166125~ (2016)
14. Cefalu WT, "Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial", Lancet, 382, pp.941~950 (2013)
15. Nauck MA, "Dapagliflozin versus glipizide as add-on therapy in patients with type 2diabetes who have inadequate glycemic control with metformin:a randomized, 52-week, double-blind, active-controlled noninferiority trial", Diabetes Care, 34, pp.2015~2022 (2011)
16. Ridderstrale M, "Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial", Lancet Diabetes Endocrinol, 2, pp.691~700 (2014)
17. Zaccardi F, "Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis", Diabetes Obes Metab, 18, pp.783~794 (2016)
18. Yoon KH, "Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials", Diabetes Obes Metab, 18, pp.1045~1049 (2016)
19. Haring HU, "Empagliflozin as add-on to metformin in patients with type 2diabetes: a 24-week, randomized, double-blind, placebo-controlled trial", Diabetes Care, 37, pp.1650~1659 (2014)
20. 민경완, "Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial", Diabetes and Metabolism Journal, 41(2), pp.135~145 (2017), 대한당뇨병학회[DOI]
21. Lavalle-Gonzalez FJ, "Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial", Diabetologia, 56, pp.2582~2592 (2013)
22. Rosenstock J, "Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2inhibitor, as add-on to metformin in subjects with type 2diabetes", Diabetes Care, 35, pp.1232~1238 (2012)
23. Rosenstock J, "Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin", Diabetes Care, 38, pp.376~383 (2015)
24. DeFronzo RA, "Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin", Diabetes Care, 38, pp.384~393 (2015)
25. Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)
26. White WB, "Alogliptin after acute coronary syndrome in patients with type 2 diabetes", N Engl J Med, 369, pp.1327~1335 (2013)
27. Green JB, "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 373, pp.232~242 (2015)
28. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
29. Wanner C, "Empagliflozin and progression of kidney disease in type 2 diabetes", N Engl J Med, 375, pp.323~334 (2016)
30. Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)
31. Kim YG, "Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians:a systematic review and meta-analysis", Diabetologia, 56, pp.696~708 (2013)
32. Hong AR, "Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial", Diabetes Res Clin Pract, 109, pp.141~148 (2015)
33. Jin SM, "Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension", Diabetes Obes Metab, 17, pp.511~515 (2015)
34. Kim MK, "Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial", Diabetes Obes Metab, 17, pp.309~312 (2015)
35. 김종호, "Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin", Diabetes and Metabolism Journal, 40(3), pp.230~239 (2016), 대한당뇨병학회[DOI]
36. Jin SM, "Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension", Diabetes Obes Metab, 17, pp.599~602 (2015)
37. Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial", Lancet, 366, pp.1279~1289 (2005)
38. Kahn SE, "Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy", N Engl J Med, 355, pp.2427~2443 (2006)
39. Kahn SE, "Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT", Diabetes, 60, pp.1552~1560 (2011)
40. Mamza J, "Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study", Ann Med, 48, pp.224~234 (2016)
41. Downes MJ, "Triple therapy in type 2 diabetes: a systematic review and network meta-analysis", PeerJ, 3, pp.e1461~ (2015)
42. Lee CM, "Triple therapy combinations for the treatment of type 2 diabetes: a network meta-analysis", Diabetes Res Clin Pract, 116, pp.149~158 (2016)
43. Lozano-Ortega G, "Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea", Curr Med Res Opin, 32, pp.807~816 (2016)
44. Mearns ES, "Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes:a network meta-analysis", Diabet Med, 32, pp.1530~1540 (2015)
45. Ahn CH, "Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study)", Diabetes Obes Metab, 19, pp.635~643 (2017)

관련 논문AI추천